Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming

Background. Sipuleucel T, an autologous cell-based vaccine targeting prostatic acid phosphatase (PAP), has demonstrated efficacy for the treatment of advanced prostate cancer. DNA vaccines encoding PAP and live attenuated Listeria vaccines have entered clinical trials for patients with prostate canc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Johnson, Laura E., Brockstedt, Dirk, Leong, Meredith, Lauer, Peter, Theisen, Erin, Sauer, John-Demian, McNeel, Douglas G.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136874/
https://ncbi.nlm.nih.gov/pubmed/30221049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1456603
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items